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Abstract
Objective: Brucella prosthetic valve endocarditis is a rare but a life-threatening complication of brucellosis. It remains a
diagnostic challenge. Optimal treatment of Brucella prosthetic valve endocarditis is debated. Available data is limited to
case reports or small case series. The purpose of this study was to systematically review all published cases of Brucella
prosthetic valve endocarditis in the literature.
Method: A systematic review of PubMed database, Google, Google Scholar, and Scopus (From January 1974 to the
present) for studies providing epidemiological, clinical and microbiological data as well as data on treatment and outcomes of Brucella prosthetic valve endocarditis was performed.
Results: A total of 51 reported cases were reviewed. Brucella melitensis (45%) and Brucella abortus (11.7%) were the
most frequently isolated species. Most common type of prosthesis valve was mechanical prothesis (84.3%) and ten
patients had double valve prosthesis (19.6%). Fever and dyspnea were present in 100% and 37.2% of the cases,
respectively. The diagnosis was set with echocardiographic ﬁnding in 30 cases (93.7%), which revealed vegetation in 27
cases (84.3%). Most used antibiotics were rifampicin, doxycycline and aminoglycoside or cotrimoxazole. No deaths were
noted in patients treated by combined medical and surgical treatment, but mortality was noted in 27.7% of the cases
treated by antibiotics alone (p ¼ 0.006).
Conclusion: This systematic review highlights diagnostic challenges and demonstrates that surgery improved outcome
by reducing mortality in patients treated with the combined surgical and medical treatment option. Brucellosis should be
considered in the differential diagnosis of prosthetic valve endocarditis in patients residing in or traveling to areas of
endemicity.
Keywords: Brucella, Endocarditis, Prosthetic valve, Antibiotics, Surgery

1. Introduction

H

uman brucellosis is a severe multisystemic
disease that may affect any organ. Focal
complications, therapeutic failure, and relapse
might occur. Cardiovascular complications are
rare, among which endocarditis is the most
common cardiovascular involvement of the disease [1]. It accounts for 0.8%e5% of all cases of

brucellosis and represents the main cause of
death due to brucellosis [2]. Mortality is usually
caused by cardiac failure especially in patients
with late diagnosis [3].
Brucella prosthetic valve endocarditis (PVE) is
extremely rare, as it remains a diagnostic and therapeutic challenge, due to the lack of controlled trials
and treatment approach regarding the ideal treatment duration, combination of antibiotics, indication and timing of surgery. The purpose of this
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study was to systematically review all published
cases of Brucella PVE in the literature and describe
the epidemiology, microbiology, clinical characteristics, treatment and outcomes of these infections.
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Abbreviations
PVE
IE

Prosthetic valve endocarditis
Infective endocarditis

2. Materials and methods
2.1. Data search
We reviewed all reported cases of Brucella PVE by
searching PubMed, Google, Google Scholar and
Scopus publications from January 1974 to the present. The used MeSH terms were: (Prosthetic valve
OR valve prosthesis OR valve replacement OR
bioprosthesis OR mechanical valve) and (brucella
endocarditis or brucellosis and endocarditis). To
ﬁnd the old publications we used MeSH "Starr's
valve and brucella endocarditis".
2.2. Study selection
We included the studies reporting data on patients’ clinical characteristics, microbiology, treatment and outcome. We included all the studies
published in different languages. The majority of
the articles were in the English language (n ¼ 33),
three articles were in French, two articles were in
Spanish and two articles were in Turkish. We
excluded from the analysis the studies which were
secondary research papers (e.g., reviews) and
studies not in humans. Brucella endocarditis on the
native valve and cardiac device were excluded.
Given the rarity of the pathology, all articles on
Brucella PVE were included in this literature review
regardless of the type of article (letter to the editor,
case report, cases included in case series) to gather
as much information as possible. Data were extracted independently by the authors and any discrepancies were reviewed and discussed until consensus
was reached, data were extracted from the reviewed
text, tables, and ﬁgures. The clinical data including
demographic characteristics, clinical features, laboratory data, echocardiographic ﬁndings, treatment,
and clinical outcome of these patients were collected
and analyzed.
2.3. Outcomes of interest
The primary outcomes were to record on the (a)
epidemiology of patients with Brucella PVE and (b)
patients' outcomes. Secondary outcomes were to
record data on (a) the exact site of infection, (b) the
patients’ clinical characteristics, (c) their laboratory
and echocardiographic features and (d) their

treatment. The identiﬁcation of risk factors for
mortality was another endpoint of this study.
2.4. Data extraction and deﬁnitions
The extracted data included patient demographic
data (age and gender); patient's relevant medical
history (previous cardiac surgery or cardiac valve
replacement, time after cardiac valve replacement);
infection data and microbiology infection site, isolated strains, presence of complications, presence of
embolic phenomena; treatment prescribed and
outcomes (cure or death).
Diagnosis of infective endocarditis (IE) was
conﬁrmed by the investigators based on information
provided by the authors and the modiﬁed Dukes’
criteria if the diagnosis was deﬁnite (2 major or 1
major and at least 3 minor criteria, or 5 minor
criteria) or if pathological data established a diagnosis of IE. The complications recorded included
any organ dysfunction or clinical deterioration that
was considered by the authors to be related to the
IE.
2.5. Statistical analysis
All of the continuous variables are expressed as
mean ± standard deviation and the categorical
variables as percentages. In univariate analysis, the
Anova test or the ManneWhitney test were used for
the quantitative variables and the Chi-square test
for the qualitative variables. A p-value < 0.05 was
considered statistically signiﬁcant. Due to the small
number of patients, a multivariate analysis was not
possible.

3. Results
3.1. Literature search
A total of 305 articles reporting Brucella endocarditis from PubMed, Google, Google Scholar and
Scopus publications were screened. After reviewing
the titles and abstracts, we identiﬁed a total of 41
articles of Brucella PVE. The full text of one article
could not be found. We included a total of 40 articles
reporting 51 cases (4e43) (Fig. 1). The ﬁrst case of
Brucella PVE has been published in 1974. Clinical,
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biological, echocardiographic and therapeutic ﬁndings are summarized in Table 1.

hunter in two patients [8,35], shepherd in ﬁve patients [8,27,30,31] and farmer in four patients
[18,38,39,42] (Table 1).

3.2. Epidemiology
Most cases were from Turkey (21 patients, 42%),
Spain (eight patients, 16%), and Iran (ﬁve patients,
10%) (Table 1). The mean age of patients was 42 ± 13
years [15e75 years], a male predominance was
noted (34 males, sex ratio 2).
3.3. Microbiology
Brucella melitensis and Brucella abortus were the
most frequently isolated species (n ¼ 29, 56.8%). B.
melitensis was isolated in 23 patients (45%), B.
abortus in six patients (11.7%) and B.suis in one
patient [35], None patient had Brucella PVE caused
by B. canis. Consumption of unpasteurized dairy
product, raw milk, fresh goat's cheese was reported
in 22 cases (43%). Contact with infected animals
and/or consumption of unpasteurized dairy milk
has been reported in 26 patients (50.9%). Thirteen
Patients (25.5%) were exposed by their profession
or by their leisure activities: veterinarian in one
patient [33], a stock- breeder in one patient [36],

3.4. Underlying cardiopathy and comorbidities
Most common type of prosthesis valve was mechanical prothesis (n ¼ 43; 84.3%), eight (15.7%)
patients had bioprosthetic valve [6e9,20,21,28,32],
And ten patients (19.6%) had double valve prosthesis [5,18,19,23,29,31,32,36,39]. Prosthetic aortic
valve involvement was reported in 27 patients
(52.9%), prosthetic mitral valve involvement was
reported in 18 patients (35.3%) and in two cases
(3.9%) both the aortic and mitral prosthesis were
affected [23,36]. No endocarditis in the tricuspid
prosthesis valve was reported (Table 2).
The etiology of the valvulopathy for which the
patient had a valvular replacement with valve
prosthesis has been speciﬁed in 27 patients. It was
rheumatic valvular heart disease in 15 of these
patients (55.5%) [4,8,11,12,15,17,18,20,21,23,24,26,
30,39] (Table 1). The average duration between
implantation of the prosthesis and the episode of
Brucella PVE was 8 ± 7 years (extremes: 4 months-

Fig. 1. Flow diagram of study inclusion.

Table 1. Clinical, biological, echocardiographic and therapeutic data of the reviewed cases of Brucella prosthetic valve endocarditis.
Authors
year

Country

Age/
sex

London/
Italian
patient

38/
M

Lezaun R
1980
(5)

Spain

48/
M

Iglesias A
1981
(6)

Spain

O’Meara
J.B
1974

Risk
factors:
Consump
tion/
professio
n
Yes

Underlying
cardiopathy

Symptoms
and physical
findings

Laboratory
findings

Serological
tests/blood
culture

TTE/TEE
findings

Complication
Cardiac/
extracardiac

Antibiotic
combinations
/total duration

Surgery/
surgical explorations
Interval time
diagnosis/surgery

Follow up

Mitral,
mechanical
Rheumatic
10 months

Fever, rigor,
cough,
dyspnea,
abdominal
pain

-

+/+
B.melitensis
B. abortus

HF

Cephalexin,
+Trimethoprim+
Sulphadiazine

Yes/V/Ischemic stroke

-

-

Double
prosthesis
aortic/mitral
5 years

Fever,
dyspnea,
petechiae
Diastolic aortic
murmur
1 month

HF

T+sulphadiazine
=3 weeks

Yes/-/negative

1 year
uneventful

Aortic
Bioprosthesi
s
Ventricular
septal patch
Congenital
heart disease
3 years
Bioprosthesi
s

Fever,
phlebitis
Signs of aortic
regurgitation
SMG

Mitral
prosthesis
stenosis in
cardiac
catheterization
Severe
paravalvular
leak on aortic
prosthesis in
cardiac
catheterization
-

Aortic,
mechanical
prosthesis
Calcified AS
23 months

Fever, chills,
dyspnea,
general
malaise
Diastolic aortic
murmur
Fever, chills
back pain,
Diastolic aortic
murmur
SMG/HMG
3 weeks
Fever, chills
SMG, HMG
Diastolic
murmur

Anemia
ESR=84/113

Anemia
ESR=28/56

+/-

Fever, chills,
aches, sweats
HMG, SMG
Diastolic
murmur
4 months

ESR=138/15
4

+/-

Fever,
dyspnea
SMG, 2ndheart
sound, the
new systolic
murmur of MR
Fever

Anemia
Hight ESR

(4)

Rubio
Alvarez
1983 (7)
Fernánde
zGuerrero
, 1987
Case 1
(8)

Spain

Fernánde
zGuerrero
, 1987
Case 2
(8)

Spain

Fernánde
zGuerrero
, 1987
Case 3

Spain

Spain

28/F

-

46/
M

No/-

60/
M

Yes/-

62/
M

Yes/
Hunter

(8)

Aortic,
mechanical
prosthesis
Rheumatic
2 years
Aortic
bioprosthesis
IE on Bicuspid
valve

+/+
B.melitensis
Initial negative
blood culture

+/+
B.melitensis

TS/12 months

Replacement of aortic
and mitral prosthesis

HF

Ts=8 weeks

Yes/A,D/
positive
Interval time diagnosissurgery: 5 days

6 months
uneventful

14months

AV block corrected by
pacemaker

Fever

No

Cured by
antibiotherapy

Anemia
ESR=66/100

+/+

-

B.melitensis

+/+

-

B.melitensis

-

-HF
-Pulmonary
edema
-atrio
ventricular
block
HF
sacroiliitis

T+S then
T/16weeks
TS
D/12 weeks after
reoperation

Yes/D, A/positive
Reoperation for
disinsertion (no IE)
Interval time diagnosissurgery: 10days

4 years
Uneventful

S+T/3weeks
T/6 weeks
S+TS/15weeks
D/24weeks

Yes/A D/positive
Reoperation for
desinsertion (no IE)
Interval time diagnosissurgery: few days

3 years
uneventful

HF

S+T/3weeks
then
D+TS/16weeks

Yes/A D/positive
B.melitensis
Interval time diagnosissurgery: 8 days

2 years
Uneventful

S+T/
then
D+TS/16weeks
D/40 Weeks

Yes/D/
positive B.melitensis
Interval time diagnosissurgery: few days

2 years
Uneventful

T+TS=3weeks

Yes/-/negative
Post-operative ischemic
stroke

Sudden death
1 year after
the
the operation,
of an unknown
cause
Uneventful

10 months

Fernánde
zGuerrero
, 1987
Case 4
(8)

Spain

33/
M

Al-Kasab
1988
(9)

Saudi
Arabia

25/F

D’Agrosa
1988
(10)

France

Flugelma
n MY
1990
(11)

Israel

Kamoun
S
1991 (12)

Tunisia

22/
M

-

A Antela
1992
(13)

Espagne

15

AM
saadeh
1996
(14)

Jordan

Mitral
valve
prosthesis
mechanica
l
Aortic
mechanica
l
prosthesis

Yes/
Shepherd

-

36/
M

-

25/
M

Yes

Aortic,
mechanical
prosthesis
Brucella
endocarditis
on native
valve
Mitral
bioprosthesis
3 years

Aortic,
mechanical
prosthesis
IE (brucella
highly
probable)
14 years
Aortic,
mechanical
prosthesis
Rheumatic
1 year
Aortic,
mechanical
prosthesis
Rheumatic
5years
Fever
2 months

Relapse after
6 months of
recovery from
brucellosis
end occult
splenic
abscess

+/-

Moderately
large V

SAT titer positif
for
B.abortus
-

+/+

A

AV Block
Myocarditis
HF

R+Quinolone

Yes/-/-

Normal

None

T+S+R=4 weeks
T+R=2 weeks

No

B.abortus

Fever,
weakness,
anorexia
Short systolic
aortic murmur
2 months
Fever

ESR=25

-

+/+
B.melitensis
SAT initially
Normal
Bone morrow
culture+
ns/+
B. Biovar I

Apyrexia
Decrease SAT
Negativation
blood culture

Valvular failure

HF

R+T
Then
R+Ofloxacin

Yes/A, D/positive

Ischemic
stroke

Antibiotherapy

Yes
Medical treatment Not
sufficient

Prolonged ATB

Yes

1 year
Uneventful

Recovery
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Table 1. (Continued).
Arslan H
1998
(15)

Turkey

Uddin
1998saa
(16)
Uddin
1998 (16)
Cakalaga
oglu C
1999
(17)

Turkey

Akinci E
2001
(18)

Turkey

27/
M

YES

Aortic,
mechanical
prosthesis
Rheumatic
4 months

Turkey
Turkey

39/F

42/
M

Yes

Yes

Mitral,
mechanical
prosthesis
Rheumatic
15 years
Double
prosthesis
Mechanical
aortic/mitral
Rheumatic
8 months

AL Soub
2001
Case 1
(19)

Qatar

29/
M

Yes

Double
prosthesis
Mechanical
aortic/mitral

Al Soub H
2001
Case 2
(19)

Qatar

39/
M

Yes

Aortic,
mechanical
prosthesis

Al Soub H
2001
Case 3
(19)
Keleş C
2001
(20)

Qatar

35/
M

Yes

Mitral,
mechanical
prosthesis

Turkey

42/F

Yes

+/+
B.Melitensis

+/+

+/-

+/ns

Fever, chills,
night sweats,
arthralgia, skin
rash, weight
loss, dyspnea
SMG, HMG
Mitral murmur
petechia
2 months
Fever, cough,
sweating,
anorexia
Hemiparesis
9 months
Fever, sweat,
anorexia
Cough
3 Weeks

ESR=45
Anemia
pancytopeni
a

+/+
B abortus

Fever, weight
loss
Sweating,
dyspnea
2 months

High ESR
Normal
WBC

B.melitensis

Aortic
Mechanical
prosthesis

Fever
Fatigue
15 days

-

Rheumatic
Mechanical
prosthesis
Mitral, Then
Bioprosthesis
mitral struck)
Aortic/Mitral
prosthesis
Rheumatic
18 years/2
years

Fever, cough,
Weakness,
dyspnea

Turkey

58/F

Yes

Mitral,
Mechanical
prosthesis
Rheumatic
28 years

Turkey

50/F

-

Aortic,
Mechanical
prosthesis
AS/ascending
aorta dilation
4 years

Longo
2008

Tunisia

(27)

49/F

55/
M

Yes
Farmer

Yes
Shepherd
Consumpti
on of raw
milk

Mitral,
mechanical
prosthesis
Rheumatic
10 years
Mitral Starr
prosthesis

Fever, sweats,
fatigue, chest
pain
4 weeks

Anemia
CRP:114
ESR:70

Fever, fatigue,
dyspnea,
HMG,
generalized
pain
Systolic
murmur
2 months
Fever, chills,
dyspnea,
chest pain
sweating,
weight loss,
arthralgia,
diastolic
murmur
2 months
Fever
3 weeks

CRP:143
ESR:47

16 years ago

Fever
Night sweating
Fatigue
5 days

S+R+TS=3
months

Yes

3 months

Uneventful

R+D+G

Yes
Prosthetic valve cultureNo

Uneventful

R+D+TS,
Replacement of
D by
ciprofloxacin
(side effects)
12 months
R+D+G
Then
R+D/3 Months

4 years
Uneventful

Yes/-/positive

7 months

Initially refused

Uneventful
Normalization
of SAT

Yes/A/
Positive
Interval time diagnosissurgery: 4days

10 months
Uneventful

V

D+S Then
D+R Then
D+R+TS/13
WEEKS

Yes/-/negative
Interval time diagnosissurgery: 10days

1 year
Uneventful

+/-

V

R+D+TS
Then
R+D/10 Weeks

Yes/-/negative
Interval time diagnosissurgery: 11 Weeks

10 months
Uneventful

+/+

V: large
Left atrium
thrombus

R+D+S
Then R+D/
6 months and 6
weeks

Yes/V/
negative

At 6 months
decreased
serology titers

-/+
B.melitensis/
Negative initial
SAT,
Coinfection
S. aureus
-/PCR positive

V (native
mitral valve)

+/+
B.melitensis

Involved
prosthesis:
aortic, mitral
V 18-11mm
A
L

V:7/4 mm

Acute
myocardial
infraction,
pulmonary
edema
Sacroiliitis,
ischemic
stroke

HF
Pulmonary
Edema

2V:12/6 mm
9/5 mm
Normal TTE

Torsade de
Pointes,
Ventricular
fibrillation

Anemia

+/+

HF

B.melitensis

Valvular
regurgitation

ESR:56

ESR=60

Yes
Prosthetic valve culture+

Interval time diagnosissurgery: 95 days

+/-

Leukopenia
ESR :70
CRP :180

R+D+G

R+D+TS/
20weeks

(23)

Italy

Ischemic
stroke

Mitral
bioprosthesis
Rheumatic
6 years

55 F

Murdaca
G
2007
(26)

Renal
insufficiency
related to
renal failure

-

German
y
Turkish
patient

(25)

Involved
prosthesis:
Mitral
V/L
Normal aortic
prosthetic

Initial SAT
normal

Fever, cough,
sweating
3 months

Al
Dhahouk
S
2006

Tasbakan
MI
2006

Brachial
mycotic
aneurysm

-/
+
Brucella
species

40/F

(24)

V/L

-

Turkey

HF

Uneventful

Involved
prosthesis:
Aortic
V/L/A

Kalayciog
lu S
2005
(22)

Sayar N
2006

L/shunt aortaleft ventricular

+/+
B.melitensis

Turkey

Yes

Fever
Dyspnea III-IV
Fever, general
malaise,
arthralgia

Anemia
ESR=90

Anemia
ESR=33

Karahoca
gil M
2005
(21)

58/
M

Fever, weight
loss, cough,
chest pain,
dyspnea,
HMG,
headache,
hemoptysis,
arthralgia,
Systolic thrill
1 month
Fever
Dyspnea III-IV

-/+

Antibiotherapy
against S.
aureus
Died before
antibiotherapy
against Brucella
D+R/ 3 months

R+D/6 months
(taken only two
months)
R+D+G=3
months
R+Ampicillin/
8weeks
G/4 Weeks
D+R+TS/12
months

D+R/3 months

No
Died

No

3 years
Uneventful

Yes/-/Initially refused

2 years
Uneventful

Yes/-/negative

12 months
Uneventful

Yes/-/positive

24 months
Normalization
SAT

Interval time diagnosissurgery: 5days

V (TEE)

R+D+G/6 weeks

No

Negativation
blood culture
Disappearanc
e of vegetation

R+D+ofloxacin=
6 months

Yes

Serologic test
became
negative within
3 months
6 months:
uneventful

Brucella
Spp
+/-

V(TTE, TEE)
6 mm

Glomerulonephritis

leucopenia
After 3 months of
antibiotic theray

Table 1. (Continued).
Botta L
2009

Bologna
Turkish
patient

68/
M

-

(28)

Gunes Y
2009
(29)

Tukey

KARAOĞ
LAN
2009
Case 1
(30)

Turkey

KARAOĞ
LAN
2009

Turkey

53/
M

42 F

27/
M

-

Consumpti
on row
milk

sheep
herder

Case 2
(30)

KARAOĞ
LAN
2009

Turkey

56/
M

Unpasteurized
milk

Case 3
(30)

KeshtkarJahromi
M
2010
Case 1
(31)

Iran

KeshtkarJahromi
M
2010
Case 2
(31)
KeshtkarJahromi
M
2010
Case 3
(31)
Sasmazel
A
2010
Case 1
(32)
Sasmazel
A
2010
Case2
(32)
Amirghofr
ane AA
2011
(33)

Iran

61/
M

Iran

16/F

Turkey

42/F

KEÇİK
BOŞNAK
2011
(34)

Turkey

Carringto
n
M
2012
(35)

USA

Mehanic
S
2012

Bosnia

(36)

34/
M

Yes
Shepherd

Yes
Shepherd

-

Aortic
Bioprosthesi
s
AS
7 months

Progressive
Fever
Dyspnea
Chills
Sweats
Weight loss
Fatigue

-

Double
prosthesis
Mechanical
Mitral/Aortic
6 years
Mitral
prosthetic
valve
Mechanical
Rheumatic
fever

Fever

ESR :60
CRP :20

Prosthetic
aortic valve
replacement
1 year
Aortic stenosis
Mechanical
prosthesis
Mechanical
aortic valve
replacement
(Rheumatic)
Fever
coronary
artery bypass
grafting for
coronary
artery disease
7 years
Double
prosthesis
Mechanical
Mitral/Aortic

headache,
dyspnea and
fever
2 weeks
systolic
murmur and

Klebsiella in only
one

WBC :11000
/mm3

fever,
dyspnea
1 month

+/+
B.melitensis

Murmur from
aortic
prosthesis
Fever
2 weeks

+/+

+/-

Surgery refused

DIED
After 1 month

Stroke

T+R+Ceftrixone/
36 Days
Further
treatment was
refused
R+D+ Amikacin

Proposed twice

Motor deficit

Then

Refused

Vegetation
disappeared
and Brucella
titers
was
decreased to
<1/160.at 12
months
Vegetation
disappeared
SAT
decreased to
<1/160
at 6 months
12 months:
uneventful
Periannular
abscess was
disappeared
and blood
cultures were
negative after
6 months
follow up 12
months:
uneventful

Interval time diagnosissurgery: 8 weeks

R+D+TS=12
mois

No

Periannular
abscess

R+D=6 months

No

Involved
prosthesis:
aortic
A/L

R+D+ciprofloxac
in/3 months

Yes/-/-

Double
prosthesis
Mitral/tricuspid

Fever
Chills
2 months
HMG

Leucocytosi
s

+/-

Involved
prosthesis:
Mitral
V 8/10 mm

Aortic
Mechanical
Prosthesis

Fever,
arthralgia
Erythema
nodosum,
purpura
30 days
Fever

Anemia

+/-

-

-

Iran

39/
M

-/
Veterinaria
n

Bentall
Aortic
Mechanical
prosthesis

Fever, chills,
hip pain,
dyspnea
2 months

-

Mechanical
aortic Valve
prosthesis
Aortic
insufficiency
4 months

Fever
Chills
Night sweating

Aortic
Mechanical
prosthesis
Four separate
aortic graft
Marfan’s
syndrome

Fever, fatigue,
malaise,
abdominal
pain, lower
back pain,
dyspnea
SMG
15 months
Subfebrile,
sweats,
dyspnea,
HMG, chest
pain

+/+
Brucella

+/+

No

A
V 8/5 mm
Aortic
aneurysm

D+R+TS+S/6
Months

Yes/-/-

<1 year

V
Mitral
Degeneration
in
bioprosthesis
Involved
prosthesis:
Mitral
V

D+R+S/6 weeks
Then
D+R/6 months

Yes/-/-

Died
10 years after
surgery
(Ischemic
stroke)
62 months
Well
Uneventful

Massive aortic
root infected
pseudoaneury
sm, normal
prosthetic
valve leaflets
vegetation

ns/+
B suis biotype I
PCR positive

Laboratory
criteria for
glomerulone
phritis

ns/+
B.melitensis
Coinfection with
Coxiella burnetti

18 years
Uneventful

Died before
antibiotherapy

B.melitensis

pancytopeni
a

6 months
Uneventful

R+D+Ceftriaxon
=1 month
Then
R+D=6 months

High ESR

Double
Mechanical
prosthesis
Mitral/Aortic
9 years

Yes/V/ positive PCR of
vegetation

B.melitensis

Fever

-/Stock
breeder

D+R/ 8 weeks
-After surgery
Cefuroxim+G+D/
2 weeks
D+G/4 weeks
D+R/3 Months

Vegetation on
aortic
prosthesis

Fever, chills
SMG
180 days

Mitral
bioprosthesis

HF

TEE
Wbc :9000
ESR : 184

Double
prosthesis
Mechanical
Mitral/Aortic

46/
M

TTE/TEE
Initially normal
Aortic valve
Severe aortic
regurgitation
on
bioprosthesis
Mitral,
regurgitation
without V
Involved
prosthesis
unknown
Normal TTE
TEE: refused
vegetation on
prosthetic
mitral
valve8x09 mm
TEE

14/6 mm

-

-/Feral
Swine
hunter

+/+

ESR=80

45/
M

46/
M

+/+
B.melitensis

B.melitensis

Turkey

75/
M

ns/+
B.melitensis

BOTH
PROSTHESIS
VALVE
INVOLVED

Shock

Surgery after 6 weeks

R+T+TS/
8 weeks
R+T/
10 months

Refused
surgery

Right coronary
involved
In the infective
process

R+Ciprofloxacin
+T+G/1 months.
R+Ciprofloxacin
+T+/10 months.

Yes/D/Bentall +CABG right
coronary artery

A
gastrointestina
l side effect of
Tetracycline

R+D+TS
Then
R+D+Ceftriaxon
=2 months
R+TS=4 months

No

Died before surgery

Shock

Pancytopenia

Multiple
Splenic infarct

Multiple splenic
infarct
Myocarditis

Severe HF

Quadruple
antimicrobial
therapy

glomeruloneph
ritis

1,5 years
Uneventful

Normalization
of biological
tests and
disappearance
of vegetation
1 year:
uneventful

No

DIED

Because cardiac
instability

In the fourth
month
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Table 1. (Continued).

Oguzhan
N
2012
(37)

Turkey

50/
M

-

Mitral
Mechanical
prosthesis
7 years

Raju T
2012
(38)

India

22/
M

-/Farmer

Lee SA

Korea

Mitral
Mechanical
prosthesis
Congenital
mitral
regurgitation
3 years
Mitral
Mechanical
prosthesis
22 years
Tricuspid
Mechanical
Rheumatic
18 years
Aortic
Mechanical
prosthesis
4 years

42/
M

-/Stock
farmer

2014
(39)

Aktürk S
2015
(40)

Turkey

Dehghan
Manshadi
SA
2016
(41)

Iran

Fonseca
JP
2018

Portugal

36/
M

35/
M

60/F

-

-

Yes/Farm
er

(42)

Hamieh
2020
(43)

Lebanon

37/
M

Yes : Row
milk intake

> 1 year
HMG, splinter
hemorrhages.
Systolic/diastol
ic murmur
Fever, fatigue,
anorexia, joint,
back pain
sweats,
cough, weight
loss, HMG,
SMG
3 months
Fever
Severe
breathlessnes
s
3 months

Fever
Dizziness
Sweats
Dyspnea
2 months

Multiple V:710mm
Atrial
thrombus
Anemia
ESR:41
CRP:43
Creat:
353,6ῃmol/l

+/ns
Hepatitis B

V15/2,5 mm
Normal TTE

-

ns/+
B.melitensis

Elevated
gradient
through mitral
prosthesis

B.abortus

Severe
anemia
CRP:57.6
mg/l
Leucopenia:
WBC: 2600

Fever, muscle
pain, back,
chest pain
New onset of
symptoms

-

Bentall
procedure
Aortic
Mechanical
prosthesis
IE complicated
with splenic
abscess
4 years
Aortic
Mechanical
prosthesis

Fever, loss of
weight, loss of
consciousness
, low back pain
4 months

-

Fever, loss of
weight, low

Mild
leukopenia
CRP:46 mg/l

AS
4 years

back pain,
asthenia
Aortic systolic
murmur
3 months
Fever, night
sweating,
generalized
fatigue
3 months

Aortic
Mechanical
prosthesis
20years

+/+
B abortus

glomeruloneph
ritis

Involved
prosthesis:
mitral

-

V (TEE)
3-8 mm

V
ns/+
B.melitensis

+/ns

V:36/11mm

Hepatitis B

Aortic
regurgitation

+/+
B.melitensis

Normal TTE
TEE:
V

+/PCR -

Prosthetic
dehiscence,
severe
paravalvular
regurgitation,
low ejection
fraction (34%)

NO

R+D+G/-

No
DIED.
Develop HF
multiorgan dysfunction
and devel
oped shock

D+R+S
Then
D+R+G
Then
D/1 years

NO
Refused
(history of three opened
cardiac surgery)

After 3 weeks:
negativation
blood culture

Disappearance of V

5 years
Uneventful
-

Acute
myocardial
infarction
related to
occlusion of
circumflex
coronary
artery
Spondylodiscit
is
meningitis

-

-

D+R+Ceftriaxon
e+G
Then R+D+TS

No
DIED
Hepatorenal and cardiac
insufficiency

Spondylodiscitis

R+D+G/3weeks
R+D/9 months

No
Judged non-necessary

No L, no A

Lactate :
87.7 mg/dl.
Procalcitonin
:0.95 ng/mL

D+R+Ceftriaxon
e/3weeks
D+R/6 weeks

(negativation
SAT)

Septic and
cardiogenic
shock

R+D/3weeks
then
R+D+G+Ceftriax
one

No vegetation
at 42 day

Shrinkage of
vegetation
2 years

Uneventful

Surgery planned but not
performed due to
hemodynamic instability
Died 24H after
admission

+: Positif, -: Negatif, ns: not specified
A: Abscess, AR: Aortic regurgitation, AS: Aortic stenosis, AV: Atrioventricular, CRP: C reactive protein, D: Prothetic valve disinsertion,(mg/l), ESR: Erythrocyte sedimentation rate mm/h, HF: Heart
failure, HMG: Hepatomegaly, IE: infective endocarditis, L: Leak, MS: mitral stenosis, MI: mitral insufficiency, MS: Mitral stenosis, PCR: Polymerase chain reaction, SAT: Serum agglutinin test, SMG:
Splenomegaly, V: Vegetation, WBC: White blood cells.
Antibiotics: R: Rifampicin, D: Doxycycline, S: Streptomycin, G: Gentamicin,T: Tetracyclin, TS: Sulfamethoxazole, and Trimethoprim.

28 years). Early Brucella PVE was noted in eight
patients [4,8,11,15,18,21,28,34]. Only three patients
had comorbidities, two patients had diabetes
[21,28] and one patient had cardiac liver cirrhosis
[39].
3.5. Clinical presentation
The commonest symptoms were fever, chills, night
sweating, dyspnea, fatigue, weight loss, osteoarticular and muscular symptoms. The mean duration of the symptoms before diagnosis was 3 ± 3
months (with extremes ranging from one week to 15
months). This duration was between two months
and one year in ten patients [8,19,31,37,38,41e43],
less or equal to two months in 24 patients
[5,8,9,11,13,17e20,22e28,30,31,33,39,40] and above
one year in four patients [6,15,35,36]. It was not
speciﬁed for the rest of the patients.

In 11 patients (21.5%), one or more hospitalizations because of fever preceded by a few weeks the
diagnosis of Brucella PVE [5,6,19,21,23,28,35,36]. In
three patients among them, the diagnosis of
brucellosis was determined but patients had failed
standard treatment for brucellosis [23,28,43]. In patients reported by Al Dhahouk et al. [23], Mehanic
et al. [36], Carrington et al. [35], and Hamieh et al.
[43], echocardiography was not performed at the
time of diagnosis of brucellosis. We can't precise
whether they had endocarditis from the beginning
or endocarditis developed later during the course of
the disease. In the patient reported by Botta et al.
[28], transthoracic and transesophageal echocardiography were normal.
A history of IE was found in six patients
[8,10,14,36,41] among them three patients [13,15,19]
had a history of Brucella endocarditis, reinfection has
occurred one year, 14 years and 6 months,

respectively. Relapse of brucellosis after an appropriate treatment was recorded in ﬁve patients
[8,10,14,33,42]. Mean duration of symptoms before
the diagnosis of PVE was also prolonged in patients
with a history of brucellosis (brucellosis with failure
of treatment, relapse, history of brucella endocarditis) [8,10,14,23,28,33,42] ranging between 2 and
4 months. Heart failure was noted in 16 patients
(31.3%).
3.6. Biological ﬁndings
Diagnosis of brucellosis was made by serology
and/or culture in all except one patient [21]. Blood
culture was positive in 31 patients (60.7%). It was
negative in 20 patients (39.3%), in these patients the
diagnosis of brucellosis was done by the serologic
tests. Both positive blood culture and serologic tests
were observed in only 23 patients (4%). Two patients with positive blood culture were seronegative
[19,26]. Results of serologic tests were not
mentioned in six patients [12,28,35,36,38,40]. PCR
test was performed in only three patients [22,35,43].
It was positive in two patients among them [22,35].
It allowed the diagnosis of brucellosis in one patient with negative blood culture and negative
serologic tests [21]. Bone marrow culture was performed in one patient, it was positive [11]. In this
patient, both blood culture and serologic tests were
positive.
3.7. Echocardiographic ﬁndings
Echocardiographic data were available in 32 patients (62.7%) (not performed in eight patients, this
technique of imaging was not developed at the time
[2e4,4e8]). Echocardiographic data of the rest of
patients were not available. It was abnormal in 30 of
them (93.7%). Twenty-seven (84.3%) patients had
vegetation, in eight patients among them a large
vegetation (size equal or above 10 mm) was noted
(29.6%) [9,20,23,24,30,31,36,41].
In three patients vegetations was detected in
transesophageal Echocardiogram, it was not shown
in transthoracic echocardiogram [24,37,42]. Six patients had abscess [1,10,23,30,31] and 11 patients had
paravalvular leak and regurgitation [15,17e19,
23,25,28,31,32,41,43].
An Aorta-left ventricle ﬁstula was seen in the
patient reported by Arslan et al. [15], a massive
aortic root infected pseudoaneurysm was reported
by Amirghofrane et al. [33] and an aortic aneurysm
was reported by Keshtkar et al. [31]. In old reports,
cardiac catheterization has shown a mitral prosthetic valve obstruction in one patient [4] and a
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severe leak in the aortic prosthetic valve in another
patient [5].
3.8. Treatment
Mean duration of treatment was 6 ± 3 months
[1e14 months]. There was no standard antibiotic
regimen used. Most used antibiotics are Rifampicin,
Doxycycline (or Tetracycline) and Aminoglycoside
(Streptomycin or Gentamycin), or Co-trimoxazole.
Co-trimoxazole (Trimethoprim-Sulfamethoxazole)
was prescribed in 16 patients (31.3%). Quinolones
(ciproﬂoxacin or oﬂoxacin) were used in six patients
(11.7%) and cephalosporin antibiotics were used in
seven patients (13.7%). Sulfadiazine was prescribed
in one patient (2%) [5] (Table 1). The effect of antibiotics on mortality cannot be assessed owing to the
small number of patients.
3.9. Comparison of medical treatment alone versus
combined surgical and medical treatment
We identiﬁed 29 patients (56.8%) who had combination of medical and surgical treatment (group 1)
[4e6,8e10,12e16,18e20,23e25,27,28,31e33] and 18
patients (35.2%) who had medical treatment alone
(group 2) [7,11,17,21,26,29,30,32,34,36e39,41e43].
Three patients (5.8%) have died before treatment
[22,31,35] (Table 3).
No difference was noted between the two groups
concerning age and sex, with p-value at 0.18 and
0.77, respectively. The mean duration of symptoms
before diagnosis was 3 ± 3 months in group 1 and
4 ± 3 months in group 2 (p ¼ 0.51). The incidence of
heart failure was similar in the two groups (p ¼ 0.22)
(Table 2). No difference was noted between the two
groups concerning positivity of blood culture
(p ¼ 0.49). The mean duration of treatment in group
1 was 6 ± 3 months [3 weeks-13 months] and in
group 2 was 7 ± 5 months [6 weeks-12 months]
(p ¼ 0.52). In patients who underwent surgery
(group 1): The median duration of antibiotics until
surgery was 10 days [5e66 days].
The most frequent indications for surgery were:
Failure of medical treatment with uncontrolled
infection and enlarging or persistence of vegetation
despite antibiotics [9,13,18,24,27,33], valvular regurgitation, and congestive heart failure in 12 patients
[4e6,8,10,12,15,23,25,28], preventing embolic complications [20], relapse after recovery by antibiotics
alone [14] and severe hemodynamic instability
which developed during antibiotic therapy [16].
Intracardiac complications with abscess in ﬁve patients [10,19,23,31] and an aortic root infective
pseudoaneurysm in one case [33] were indication
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Table 2. Clinical presentation and complications of the reviewed cases.
Number

Percentage (%)

References

51
19

100
37.2

Night sweating
Fatigue, asthenia, weakness
Chills

15
14
12

29
27
23.5

Osteoarticular symptoms

10

19.6

Splenomegaly

9

17.6

Hepatomegaly

9

17.6

Weight loss
Associated sites
Sacroiliitis

7

13.7

[4e43]
[4,5,8*,9,15,16**,20,21,38,24,25,28,30***,33,35,36,39]
*Case 1,**Case 1,2, ***Case 1,2
[8,18e20,23,25,27,28,34,36,37,39,43]
[11,18,21e25,27,28,35e37,42,43]
[8*,18,25,28,31**,33,34,36]
*Case 1,2,3; **Case 1,2,3
[8*,15,17,18,24,25,33,35,27,40,31**]]
*Case 4, **Case 3
[6,8*,9,18,31,35,37]
*Case 2,3,4
[8*,15,18,24,31**,36,37]
*Case 2,3,4; **Case 2
[15,18,20,25,28,37,42]

2

3.9

Spondylodiscitis
Underlying cardiopathy
DVP: Mitral and aortic prosthetic

2

3.9

8

15.6

DVP: Mitral and tricuspid prosthetic
Aortic prothesis

2
21

3.9
41

Mitral prothesis

14

27.4

2
1

3.9
1.9

16

31.3

1
2
2
1
1
1
4
3
1
1
2

1.9
3.9
3.9
1.9
1.9
1.9
7.8
5.8
1.9
1.9
3.9

Clinical presentation
Fever
Dyspnea

Bentall intervention
Aortic graft and mechanical aortic prosthesis
Complications
Heart failure
Septic shock
Myocarditis
Myocardial infraction
Rhythm disturbance
Atrioventricular block
Artery mycotic aneurysm
Ischemic stroke
Glomerulonephritis
Renal failure
Meningitis
Multiple splenic infract

[8*,21]
*Case 2
[41,42]
[5,18,19*,23,29,31**,32***,36]
*Case 1,**Case 1,***Case 2
[31] Case 2, [39]
[6,8*,10e12,14,15,19**,22,25,28,30***,31****,40,42,34]
*Case 1,2,3,4; **Case 2; ***Case 2,3,****Case 3,43
[4,9,13,17,19*e21,24,26,27,30**,32***,37,38]
*Case 3, **Case 1, ***Case 1
[33,41]
[35]
[4e6,8*,10,12,15,22,23,25,28,36,38,41,43]
*Case 1,2,3
[43]
[10,35]
[22,40]
[24]
[10]
[17]
[13,19,21,30]
[27,36,37]
[18]
[41]
[14,35]

DVP: Double valve prosthesis.

for surgery. In two patients, surgery was initially
refused and performed later when antibiotic therapy alone was inefﬁcient [18,23].
The echocardiographic ﬁndings were conﬁrmed
during surgery in all the patients except the patient
reported by Amirghofrane et al. [33], prosthetic valve
disinsertion was noted intraoperatively but not
shown in echocardiography. In ﬁve patients in whom
echocardiography was not performed (the technique
was not developed at the time), surgical examination
revealed abscesses in ﬁve patients [6,8,12] and
dehisced prosthetic valve in six patients [6,8,12].
Culture of vegetation, excised tissues, or prosthesis
valve was positive in ten patients [6,8,16,18,19,25,28]. All

of them had positive blood culture except two patients
[8], among whom the diagnosis of brucellosis was
determined by serologic tests. In three patients
[18,23,28], culture of the prosthesis was positive despite
appropriate and prolonged antibiotics, with treatment
duration respectively at 95 days, 2 months, and 8 weeks.
All patients who underwent surgery were cured
by combination surgery and antimicrobial therapy
(Fig. 2). Few postoperative complications have been
reported, including a regressive ischemic stroke in
two patients [4], atrioventricular block treated by a
pacemaker in one patient [6], and reoperation in two
patients for desinsertion of the valve prosthesis
without signs of endocarditis [8].

Seventeen patients had antibiotic therapy alone
(group 2), among them 13 patients have been cured
[7,11,17,21,26,30,32,34,37,39,42] and four patients
have deceased [29,36,38,41] (Fig. 2). In patients cured
by antibiotic therapy alone, surgery was planned
but refused by the patients in three cases [30,32,39].
In the other patients [7,11,17,21,26,30,34,37,42], surgery was not performed because there were no
heart failure and prosthetic dysfunction with good
evolution and disappearance of vegetation. In group
2, therapeutic choice (medical treatment alone) was
consistent with current guidelines [48] in all these
patients except in the patient reported by karao
glan
et al. [30] in which cardiac abscess was treated by
antibiotics alone, and the patient reported by
Mehanic et al. who had heart failure [36].
The average follow-up was 1 year [0,5e18 years],
no signiﬁcant difference was noted between the two
groups (p ¼ 0.56). Neither relapses nor late death
related to Brucella PVE was noted in the two groups.
Sudden death of unknown cause has occurred in
one patient one year after surgery [9].
3.10. Early mortality
Early mortality was noted in 16% of the cases (8/50
patients). There was no information about treatment
in one patient. Five patients were treated with antibiotics alone, and three patients with PVE died
before the diagnosis of brucella PVE [22,31,35]. No
deaths were noted in patients treated by combined
medical and surgical treatment, but mortality was
noted in 27.7% of the cases treated by antibiotics
alone (5/18). Table 4 summarize clinical and paraclinical data in deceased patients compared to cured
patients.
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4. Discussion
Human Brucellosis is the most frequently
encountered world-wide zoonotic disease, it affects
both adult and child and remains a major human
health problem in many developing regions, especially in the Mediterranean basin, North and East
Africa, the Middle East, the Arabian Peninsula, the
Indian subcontinent and parts of South America and
Central Asia [44,45]. According to the World Health
Organization, 500,000 new Brucella cases are reported
each year with a prevalence of more than 10/100,000
population is noted in endemic countries [46].
4.1. Clinical presentation and risk factors of
brucellosis
As noted in this review, the disease affects mostly
the young population. The infection is usually
associated with contact with infected animals or
through the consumption of unpasteurized dairy
milk [44]. A careful assessment of epidemiological
risk factors is crucial for the diagnosis of brucellosis.
In reported cases, these risk factors were not sought
in nearly half of the patients. Clinicians should
obtain information about patient activities including
travel, food consumption, occupation, and outdoor
recreation. Brucella species should be considered in
the differential diagnosis of PVE in patients leaving
or returning from a region of endemicity. This review emphasizes the importance of performing a
detailed patient interview, as it can provide useful
information regarding potential exposure to infectious agents.
Human brucellosis is a multisystemic disease with
a large spectrum of symptoms [2]. In the cases

Table 3. Clinical, biological, echocardiographic data among patients treated with combined treatment (group 1) and patients treated by antibiotic
therapy alone (group 2).
Age (years)
Gender (male)
Duration of symptoms before diagnosis (months)
Heart failure
Double prosthesis
Mechanical prosthesis
Prosthetic disinsertion
Cardiac abscess
Negative blood culture
Follow up duration (years)
Mean duration of antibiotherapy (months)

Group 1 (n ¼ 29)

Group 2 (n ¼ 18)

P-value

40 ± 14
18
3±3
10
4
19
15
10
12
2±4
6±3

45 ± 13
15
4±3
5
5
17
2*
1**
5
4±3
7±5

0.18
0.77
0.51
0.22
0.45
0.09
0.002
0.04
0.49
0.56
0.52

Group 1: patients treated with medical and surgical treatment, group 2: patients treated with medical treatment alone. Bold value indicates the difference between the groups was signiﬁcant (p < 0.05).
*Two patients with disinsertion of the prosthesis were not received surgery, in the patient reported by Cakalagaoglu C, medical
treatment was chosen as the adequate treatment option, and in the second patient, surgery wad planned but the patient is deceased
before. ** Brucella prosthetic valve endocarditis complicated with periannular abscess treated with antibiotherapy alone.
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Fig. 2. Early mortality among treatment group and medical treatment
alone group (Surgery þ : Combined medical and surgical therapy,
Surgery -: Medical treatment alone).

analyzed here, the spectrum of symptoms is closer
to that of brucellosis than that of PVE. In patients
with a prosthetic valve, brucellosis must be evoked
when fever is associated with night sweating, muscle pain, arthralgia, back pain, and spondylodiscitis,
especially in patients with risk factors. Relapse of
brucellosis was noted in ﬁve patients. Relapsing
bacteriemia after appropriate treatment for acute
brucellosis is an important clue for the diagnosis of
brucella endocarditis in patients who have prosthetic valves [8,10,14,33,42].
In this current review, heart failure was frequent
and represented a risk factor of mortality. It remains
the most common cause of death due to IE and the
most frequent reason for surgery in these patients
[3,28].
4.2. Diagnosis work-up and challenges
Brucella PVE remains a diagnostic challenge.
Meticulous history taking, clinical examinations,

and detailed laboratory tests such as serologic tests
and blood culture, and echocardiography are
required through the diagnosis process. In the
reviewed cases, prolonged interval time between
the onset of symptoms and diagnosis of Brucella PVE
was noted. This interval time was prolonged even in
patients with a known history of brucellosis. The
delayed diagnosis can be explained by the difﬁculty
in the culture of Brucella species and the lack of
speciﬁcity of symptoms. Brucellosis is often misdiagnosed. By screening for Brucella antibodies of all
sera from febrile patients, Purwar et al. reported
almost two new cases per month of brucellosis, most
of which are not suspected by clinicians [47]. According to some authors, Serious damage is likely to
be caused not so much by the supposed poisonousness of the bacteria as by a late diagnosis due to
the difﬁculty in the culture of this agent [48]. Special
attention is then necessary for patients with prosthetic heart valves.
In cases reviewed here, a high rate of negative
blood culture was noted (39.3%). Brucella endocarditis is often culture-negative endocarditis. In
many series, it forms part of the pool of cases of
pathogen-induced endocarditis with negative blood
cultures. A negative culture could potentially lead to
a delay in diagnosis and treatment [31]. Blood cultures, although highly speciﬁc, present a low
sensitivity (15e70%) due to the low growth rate of
Brucella spp., the necessity of proper culture medium, and their fastidiousness. In patients with PVE
and negative blood culture, a high degree of suspicion of brucella PVE is needed especially in young
male patients with a history of exposure to farm
animals.
Due to the lack of sensitivity of blood cultures,
serology is being used increasingly to allow an early
diagnosis and is a major criterion in Duke's criteria
[49]. However, serologic tests are not wholly speciﬁc, may be difﬁcult to interpret in endemic areas,
and maybe negative during the early stages of the

Table 4. Clinical and paraclinical data in deceased and cured patients.

Heart failure*
Age (Years)
Gender (male)
Negative blood culture
Large vegetation
Antibiotherapy alone/combined treatment**
Desinsertion of the valve prosthesis
Intracardiac abcess

Deceased patients
(n ¼ 8)

Cured patients
(n ¼ 43)

P-value

5
45 ± 13
8
5
3
8/0
0
0

10
41 ± 14
25
25
4
10/29
16
11

0.04
0.50
0.06
0.6
0.04
0.006
0.01
0.26

OR: Odds ratio, CI: Conﬁdence interval.
*Heart failure at admission, **Combined treatment: Surgery combined with medical treatment (antibiotherapy).

disease. They are considerably more reliable in the
diagnosis of brucellosis when evaluated together
with a consistent clinical presentation. In the majority of the cases reviewed here, the diagnosis was
made initially by the serologic tests.
In this review, two seronegative patients with
positive blood culture were reported. In literature
about Brucella endocarditis, 6% of the patients with
acute brucellosis present with an initial titer 1/160,
but it becomes at least four-fold higher on subsequent testing [50]. According to some authors,
serologic tests are not suitable for the follow up of
patients since titers can remain high for a prolonged
period [51]. The high sensitivity and speciﬁcity of
the PCR assays may provide a valuable tool for the
diagnosis of brucellosis which is the case of the
patient reported by Kalaycioglu et al. [22].
In cases reviewed here, echocardiography played
a crucial role in the diagnosis of Brucella PVE and its
complications. When available, echocardiography
has been used as the ﬁrst-line diagnostic approach
and it allowed the diagnosis of endocarditis in the
majority of cases. Some authors [52] recommended
echocardiography in all patients with Staphylococcus aureus bacteremia because of the high frequency of endocarditis in such cases and because of
the high morbidity and mortality of S. aureus
endocarditis. In the same vein, can we suggest the
systematic practice of echocardiography in all patients with cardiac valve prosthesis and brucellosis.
This suggestion is supported by analyzing the
echocardiographic ﬁndings in reviewed cases.
Brucella PVE was misdiagnosed in some febrile
patients or patients with a conﬁrmed diagnosis of
brucellosis because repeated echocardiography has
not been done [19,23,33,35,36,42,43].
Brucella spp. can cause destruction and ulceration
in tissues slowly, explaining the frequency of paravalvular leakage reported in 19 cases (37.2%)
(revealed by echocardiography, cardiac catheterization, and surgical examination) and abscesses
reported in 11 cases (21.5%) (revealed by echocardiography and surgical examination). These intracardiac complications reﬂect the severity of the
disease. When compared with other bacterial
pathogens, Brucella endocarditis is characterized by
a greater tendency toward ﬁbrosis, hyalinization,
and calciﬁcation involving the cardiac valves.
Therefore, due to its rapid and wide tissue
destruction, higher mortality rates were observed
during this disease [1,38,39,49] and has been noted
in this review. Nearly the third of reviewed cases
have large vegetation, which could be explained by
the diagnostic delay and the prolonged evolution
before the echocardiography is performed.
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4.3. Treatment approach
Owing to the lack of large series, the optimal
association, and duration of antibiotics is unknown. The intracellular location of the microorganism makes it inaccessible to the action of many
antibiotics [53]. Ideally, the antimicrobial agent
should be bactericidal to prevent relapse in
brucellosis [54]. According to some authors, the
addition of a third-generation cephalosporin (ceftriaxone), to the combination of a tetracycline
group and rifampicin was more effective than
aminoglycosides [55]. Quinolones such as oﬂoxacin
and ciproﬂoxacin are the alternative drugs in
combination therapy of brucellosis. They can be
included due to their great tissue distribution and
a great capacity to penetrate in vegetations in patients with IE and PVE [48].
Long-term treatment is necessary for Brucella
infection since it is an intracellular and antibioticresistant infection [49,56]. By analyzing data of
reviewed cases, it seems to be unanimous agreement on the need to prolong the Brucella PVE
therapy, but there is no ﬁxed duration in all patients.
The mean duration of antibiotics varied from 1
month to 14 months. Prolonged therapy is necessary, before and after surgery, mostly in patients
with prosthesis valve culture positive. In current
guidelines, a duration of over 3e4 months was recommended in patients with Brucella endocarditis
[49]. We believe that a longer duration of antibiotics
may be necessary in cases of Brucella PVE.
Combined treatment associating surgery and
medical treatment versus medical treatment alone
was debated. Although recovery has been reported
with antibiotics alone, surgery after medical treatment has been adopted as the most common
therapeutic approach. In articles reviewed here
[4e6,8e10,12e16,18e20,23e25,27,28,30e33,39] and
in the literature about Brucella endocarditis (on the
native valve and prosthetic valve) [22,56,57], authors suggest an early surgical approach with
preoperative antibiotic therapy and immediate
surgery after clinical stabilization due to the degree
of tissue ulceration and destruction caused by
Brucella. The high rate of recurrence and resistance
of Brucella to medical treatment and development
of large vegetations carrying a signiﬁcant risk of
embolization [25]. Other studies reported cases of
Brucella endocarditis cured by antibiotics alone
[7,11,17,21,26,30,32,34,37,39,42,58e60]. They stress
the need for prognostic stratiﬁcation of each case
and support conservative treatment in low-risk
cases without cardiac failure and with a short disease interval medical treatment. According to
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them, careful monitoring is necessary because
recurrence risk is high. All cases of Brucella endocarditis cured by medical therapy alone were
reviewed by Mert et al. [58], who thought that the
probable success of medical therapy was attributable to the absence of the compelling indications
for surgery, such as heart failure, valve destruction,
abscess formation or prosthetic valves dysfunction.
The results of this literature review support the
opinion of the authors that believe that surgery is the
most efﬁcient approach for the treatment of Brucella
PVE by showing a signiﬁcant decrease in mortality in
the group of patients treated with surgical treatment
compared to the group of patients treated with antibiotics alone. Moreover, this superiority of surgical
treatment was observed despite the lack of difference
between the two groups in terms of clinical presentations. Given the slowly destructive character of
Brucella. Spp., relapses, the multiple antibiotics
needed to control this infection, her prolonged
duration and the improved outcome with surgery,
the question that arises is “Can we add Brucella
species to the microorganisms listed in the guidelines related to the management of IE (Staphylococci
or non-HACEK gram-negative bacteria and fungi)
[49] to be considered as an indication for surgery?”.
However, the number of patients reviewed here is
limited which does not allow a recommendation.
4.4. Limitations
Although this review is the only and the largest
one evaluating the diagnosis and therapeutic
approach in Brucella PVE, it relies entirely on
retrospectively published data, in some cases,
crucial information is missing. Another important
limitation is the small number of patients resulting
in restricted statistical analysis. Therefore, the results of the survival analysis could not be extended
by multivariate analysis. Moreover, because the review spanned many decades, during them the
diagnosis, deﬁnition, surgical indication, and antibiotic treatment of endocarditis changed, this must
be considered a limitation in interpreting the data.

5. Conclusion
This review points out the main reported characteristics of Brucella PVE, highlights the difﬁculties in
its diagnosis. Brucella spp. should be considered as
one of the etiologic agents of PVE in patients living
or returning from endemic region, with a history of
ingestion of unpasteurized dairy products and/or
exposure to animals with prolonged and unexplained fever especially in patients with negative

blood culture and clinical signs suggestive of
brucellosis that must be carefully researched. Earlier
diagnosis and treatment lead to decreasing
morbidity and mortality related to this infection.
Optimal treatment of Brucella PVE is a subject of
great controversy. We suggest that successful management of Brucella PVE requires a combination of
medical and early surgical therapy to achieve the
sterilization of infected cardiac tissue and to replace
the infected prosthesis valve, but given the limited
number of patients, a formal therapeutic approach
cannot be validated.

Summary section
Brucella prosthetic valve endocarditis affects
mostly the young population with risk factors.
Brucella prosthetic valve endocarditis is usually
culture-negative endocarditis. High rate of negative
blood culture was reported, in almost 40% of the
cases.
Echocardiography has a crucial role in the diagnosis of Brucella prosthetic valve endocarditis and its
complications.
Although recovery was reported with antibiotics
alone, combined medical and surgical therapy is the
most efﬁcient therapeutic approach as a signiﬁcant
decrease in mortality was reported.
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